UT MD Anderson is home to the Therapeutics Discovery Division, a dynamic engine advancing the future of cancer therapies. This division removes traditional bottlenecks in drug discovery through a multidisciplinary approach that brings together researchers, clinicians, drug developers, and scientific experts to rapidly move novel therapeutics from concept to clinical use. Within this collaborative ecosystem, the Institute Research Investigator in Radiotherapeutics Chemistry plays a critical role in translating innovative scientific discoveries into life-saving treatments.
UT MD Anderson is a leading institution focused on cancer care, research, education, and prevention. The Institute Research Investigator in Radiotherapeutics Chemistry contributes directly to the RADIATE platform, an industrialized translational research unit dedicated to radiopharmaceutical drug discovery and development. Through integrated platforms, advanced data science, and patient-centered research, the Instit...